Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 12:14:972-976.
doi: 10.18632/oncotarget.28537.

Melatonin and carcinogenesis in mice: the 50th anniversary of relationships

Vladimir N Anisimov #  1 , Alexey G Golubev #  1
Affiliations

Melatonin and carcinogenesis in mice: the 50th anniversary of relationships

Vladimir N Anisimov et al. Oncotarget. .

Abstract

The history of studies of melatonin effects on cancer in mice is outlined, the main lesson being that the systemic in vivo effects of melatonin on animals may overwhelm the in vitro effects found using tissue explants or cell cultures. In particular, the timing of melatonin administration is of crucial importance for using the drug, which is freely available over counter and thus needs no licensing for its applications in oncology.

Keywords: cancer; melatonin; mice.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

Authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1. Trends in the annual numbers of publications.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Anisimov VN, Morozov VG, Khavinson VKh, Dil’man VM. Sopostavlenie protivoopukholevoĭ aktivnosti ékstraktov épifiza, gipotalamusa, melatonina i sigetina u mysheĭ s perevivnym rakom molochnoĭ zhelezy [Comparison of the anti-tumor activity of extracts of the epiphysis and hypothalamus, melatonin and sigetin in mice with transplanted mammary gland cancer]. Vopr Onkol. 1973; 19:99–101. - PubMed
    1. Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta. 2006; 1757:573–89. 10.1016/j.bbabio.2006.03.012. - DOI - PubMed
    1. Mihanfar A, Yousefi B, Azizzadeh B, Majidinia M. Interactions of melatonin with various signaling pathways: implications for cancer therapy. Cancer Cell Int. 2022; 22:420. 10.1186/s12935-022-02825-2. - DOI - PMC - PubMed
    1. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem. 2002; 2:113–32. 10.2174/1568026023394407. - DOI - PubMed
    1. Bartsch H, Bartsch C. Effect of melatonin on experimental tumors under different photoperiods and times of administration. J Neural Transm. 1981; 52:269–79. 10.1007/BF01256752. - DOI - PubMed